The addition of
sitagliptin 100 mg/day produced a statistically significant reduction in mean HbA1c level (mean HbA1c reduction of 0.99±0.85%, P<0.01). In the group taking a combination of
sitagliptin and
metformin (n=143, initial mean HbA1c level=7.48%), the reductions in HbA1c, 2-hour postprandial
glucose, and fasting
glucose levels were 0.72±0.76% (P<0.01), 47±65 mg/dL (P<0.01), and 15±44 mg/dL (P<0.01), respectively. In the group taking a combination of
sitagliptin,
glimepiride, and
metformin (n=125, initial mean HbA1c level=8.42%), the reductions in HbA1c, 2-hour postprandial
glucose, and fasting
glucose levels were 1.09±0.86% (P<0.01), 62±64 mg/dL (P<0.01), and 31±45 mg/dL (P<0.01), respectively. In the group taking a combination of
sitagliptin,
glimepiride,
metformin, and α-
glucosidase inhibitor (n=63, initial mean HbA1c level=9.19%), the reductions in HbA1c, 2-hour postprandial
glucose, and fasting
glucose levels were 1.27±0.70% (P<0.01), 72±65 mg/dL (P<0.01), and 35±51 mg/dL (P<0.01), respectively. In the group that had previous
hypoglycemic events and that changed from
glimepiride to
sitagliptin, HbA1c level did not change but fasting
glucose increased significantly (14±29 mg/dL, P<0.01).
CONCLUSION: